Figure 6.

The tumorigenicity of CD133⁺/CD44⁺ cells derived from MDA-MB-231Luc tumors. (A): FACS analysis demonstrated that the CD133⁺/CD44⁺ subpopulation was enriched after a 3-week treatment of docetaxel (15 mg/kg). (B): Study design for the isolation and reimplant of CD133⁺/CD44⁺ and CD133⁻/CD44⁻ cells. The cells were isolated and sorted after docetaxel treatment. The cell doses for reimplant were 10, 100, 1,000, and 10,000 cells for each of the experimental groups (10 mice per group). (C): The tumorigenic frequency of CD133⁺/CD44⁺ or CD133⁻/CD44⁻ subpopulations. (D): The representative bioluminescence imaging images of the tumor-bearing mice transplanted with 10,000 cells. Abbreviations: FACS, fluorescence-activated cell sorting; Tx, treatment; SOC, standard of care agent.